Abbott plans to offer updated FreeStyle Libre 2 and Libre 3 sensors in the US later this year, replacing its current systems.
Automated insulin delivery (AID) systems include an insulin pump that communicates with a continuous glucose monitor, which can adjust the amount of insulin administered to a user based on real-time glucose data.
However, while Abbott sees the opportunity in serving new patients, others do not expect a material change in CGM demand for either Abbott or its competitor Dexcom, partly because AID systems are primarily used by people with Type 1 diabetes, and are already used by more than half of the US market. Most of the future growth for CGMs in the US is expected to come from people with Type 2 diabetes who use insulin. As such, the recent announcement may be more impactful for AID players such as Tandem and Insulet, as Abbott’s reach and market share — particularly internationally — could benefit these companies.
The company is currently working with insulin-pump makers Insulet and Tandem for future integrations. In Germany, the Libre 3 sensor is authorized to work with the mylife Loop solution made by Ypsomed and the CamAPS app, with future launches planned in the UK, Switzerland and the Netherlands.
To read more, CLICK HERE
